br References br www who int gho publications
 www.who.int/gho/publications/world health statistics/2017.
 M. Rahman, M. Mahmoudi, Colloidal Nanoparticles for Biomedical Applications X, International Society for Optics and Photonics, 2015, 93380V.
Giulio Caracciolo is Associate Professor at the Molecular Medicine Department of the Sapienza University of Rome where he established the NanoDelivery Lab in 2010 and has been acting as the Principal Investigator since. Prof. Caracciolo is contributing to explore the bionano inter-actions, i.e. the mechanisms governing the interactions of nanosized systems with living organisms with particu-lar emphasis on liposomes and hybrid nanomaterials. This knowledge will allow researchers to develop new targeted therapeutics and platforms for early disease detection.
Hojatollah Vali began his career at the Technical Uni-versity in Munich and moved to Canada in 1989 to join McGill University after a short tenure at CalTech. Vali is currently Full Professor in the Department of Anatomy
& Cell Biology and founder and Director Emeritus of the Facility for Electron Microscopy Research (FEMR). Over a SCH 772984 of 30 years, Dr Vali has acquired an exceptional ability to determine processes occurring at the interface between inorganic and organic phases in both natural and synthetic systems. Vali’s expertise in research on magne-totactic bacteria led to his collaboration with Dr David McKay at NASA-Johnson Space Center in 1996 to inves-tigate ancient life in Martian meteorite ALH84001 and the
controversial publication in the journal Science.
Dr. Anna Moore is a Professor of Radiology and an Assis-tant Dean at the College of Human Medicine and Director of Precision Health Program at Michigan State University. Dr. Moore’s research is aimed at developing molecular imaging theranostic agents for cancer and diabetes. Her studies led to the first demonstration of delivery of non-coding RNAs to solid tumors using magnetic resonance imaging. She has published her research in high impact journals and is a recipient of multiple grants from NIH and other agencies. She has served as a member of the Board of Trustees of the World Molecular Imaging Society.
Dr. Morteza Mahmoudi is an Assistant Professor of Radi-ology and Precision Health Program at Michigan State University (MSU). Prior coming to MSU, he was an Assis-tant Professor of Anesthesiology at Brigham and Women’s Hospital, Harvard Medical School. His specific research interest is in nanomedicine and regenerative medicine for the development of new nano-based platforms for pre-vention/treatment of life-threatening conditions such as cardiomyopathy, cancer, and neurodegenerative diseases. He is among 2018 highly cited researchers in 2018 as reported by Clarivate Analytics.
Thoracic: Lung Cancer Moore et al
Challenging 30-day mortality as a site-specific quality metric in non–small cell lung cancer
Carrie B. Moore, MD, PhD,a Morgan L. Cox, MD,a Michael S. Mulvihill, MD,a Jacob Klapper, MD,b
Thomas A. D’Amico, MD,b and Matthew G. Hartwig, MD, MHSb
Objective: The objective of exothermic project was to assess the best measure for post-operative outcomes by comparing 30-day and 90-day mortality rates after surgery for non–small cell lung cancer using the National Cancer Database. Secondarily, hospital performance was examined at multiple postoperative intervals to assess changes in ranking based on mortality up to 1 year after surgery.
Methods: Patients who had undergone surgery for non–small cell lung cancer be-tween 2004 and 2013 were identified in the National Cancer Database. Mortality rates at 30 days and 90 days were compared after adjusting for several patient characteristics, tumor variables, and hospital procedural volume using general-ized logistic mixed models. Subsequently, mixed model logistic regression models were employed to evaluate hospital performance based on calculated mor-tality at prespecified time points.
Results: A total of 303,579 patients with non–small cell lung cancer were included for analysis. The 90-day mortality was almost double the 30-day mortal-ity (3.0% vs 5.7%). Several patient characteristics, tumor features, and hospital volume were significantly associated with mortality at both 30 days and 90 days. Hospital rankings fluctuate appreciably between early mortality time points, which is additional evidence that quality metrics need to be based on later mortality time points.
Conclusions: Thirty-day mortality is the commonly accepted quality measure for thoracic surgeons; however, hospital rankings may be inaccurate if based on this variable alone. Mortality after 90 days appears to be a threshold after which there is less variability in hospital ranking and should be considered as an alternative quality metric in lung cancer surgery. (J Thorac Cardiovasc Surg 2019;158:570-8)